Maryland Medicaid spending on GLP-1 drugs

How much did Maryland Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $142.8 million for GLP-1 drugs paid through Maryland Medicaid in 2025, across at least 148,648 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 119 rows of 308, so these figures are floors.

Pharmacies were reimbursed at least $39.7 million for GLP-1 drugs paid through Maryland Medicaid in 2026 (quarter 1 only, as posted so far), across at least 39,617 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 39 rows of 94, so these figures are floors.

By year and ingredient

2020at least $13,197,670No dataat least $7,246,583at least $20,304,139at least $250,758Suppressedat least $152,008at least $61,682at least $41,212,840
2021at least $23,707,210No data$6,252,905at least $31,433,807at least $193,705Suppressedat least $240,725Suppressedat least $61,828,352
2022at least $40,407,958at least $352,436at least $4,155,699at least $42,998,804at least $229,530Suppressedat least $286,251Suppressedat least $88,430,678
2023at least $62,046,132at least $3,651,105at least $2,949,352at least $48,298,191at least $238,614Suppressedat least $319,287at least $21,099at least $117,523,780
2024at least $80,423,373at least $12,621,248at least $1,081,011at least $35,384,921at least $203,102No dataat least $274,432Suppressedat least $129,988,086
2025at least $105,952,028at least $21,545,487at least $812,036at least $14,324,829at least $31,709No dataat least $146,900Suppressedat least $142,812,988
2026 (Q1)at least $29,479,193at least $8,755,539at least $139,282at least $1,261,916SuppressedNo dataat least $25,274No dataat least $39,661,203

By product, 2025

Ozempicat least $97,344,591at least 101,2666 of 38
Rybelsusat least $7,142,576at least 7,4658 of 24
Wegovyat least $1,464,861at least 1,1404 of 24
Mounjaroat least $19,571,755at least 18,44624 of 63
Zepboundat least $1,973,732at least 1,90921 of 38
Liraglutide (generic name listing)at least $812,036at least 2,63422 of 43
SaxendaSuppressedSuppressed2 of 2
VictozaSuppressedSuppressed3 of 3
Trulicityat least $14,324,829at least 15,58816 of 55
Bydureonat least $31,709at least 391 of 2
ByettaSuppressedSuppressed2 of 2
Soliquaat least $146,900at least 1614 of 8
XultophySuppressedSuppressed6 of 6

By quarter, 2025

Q1 2025at least $32,685,745at least 34,30924 of 71
Q2 2025at least $35,332,548at least 36,68431 of 76
Q3 2025at least $37,088,233at least 38,55332 of 80
Q4 2025at least $37,706,462at least 39,10232 of 81

By quarter, 2026 (posted so far)

Q1 2026at least $39,661,203at least 39,61739 of 94

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.